Accord Healthcare Receives Positive CHMP Opinion for Imuldosa
19 Oct 2024 //
PR NEWSWIRE
Alvotech`s Biologic Selarsi (Ustekinumab) Receives Approval in US
18 Oct 2024 //
FDA
Lilly reports Ph 3 study of mirikizumab compared to ustekinumab for Crohn
15 Oct 2024 //
PR NEWSWIRE
US FDA Approves Dong-A ST’s Imuldosa, a Biosimilar to Stelara
11 Oct 2024 //
BUSINESSWIRE
Accord`s Biologic Imuldosa (Ustekinumab) Receives Suppl Approval in US
10 Oct 2024 //
FDA
Fresenius & Formycon Receive FDA Approval For Biosimilar Otulfi
30 Sep 2024 //
BUSINESSWIRE
Fresenius Kabi`s Biologic Otulfi (Ustekinumab) Receives Approval in US
27 Sep 2024 //
FDA
Samsung Bioepis`s Eksunbi (ustekinumab) Receives Approval in Europe
12 Sep 2024 //
EMA
Celltrion`s Steqeyma (ustekinumab) Receives Approval in Europe
11 Sep 2024 //
EMA
EC Approves Celltrion`s SteQeyma For Multiple Inflammatory Diseases
26 Aug 2024 //
BUSINESSWIRE
Teva Reports Strong Q2 Growth, Raises 2024 Guidance
31 Jul 2024 //
GLOBENEWSWIRE
Sandoz Launches Biosimilar Pyzchiva For Chronic Inflammatory Diseases
24 Jul 2024 //
GLOBENEWSWIRE
STADA And Alvotech Launch Uzpruvo, First Ustekinumab Biosimilar In Europe
23 Jul 2024 //
PHARMABIZ
STADA And Alvotech Launch Uzpruvo, First Ustekinumab Biosimilar In EU
22 Jul 2024 //
GLOBENEWSWIRE
Amgen`s Wezenla (ustekinumab) Receives Approval in Europe
18 Jul 2024 //
EMA
J&J beats Wall St estimates on strong drug sales ahead of Stelara competition
18 Jul 2024 //
REUTERS
Samsung Bioepis’ PYZCHIVA Approved by FDA as Biosimilar of Stelara
01 Jul 2024 //
CONTRACT PHARMA
FDA approves biosimilar Pyzchiva (Ustekinumab-ttwe), to be commercialized in US
01 Jul 2024 //
GLOBENEWSWIRE
FDA Approves PYZCHIVA® (ustekinumab-ttwe), Samsung Bioepis’ Biosimilar
01 Jul 2024 //
GLOBENEWSWIRE
TREMFYA Studies Show Potential For SC And IV Induction As IL-23 Inhibitor
20 Jun 2024 //
PR NEWSWIRE
Alvotech and STADA add to strategic alliance through denosumab partnership
12 Jun 2024 //
PRESS RELEASE
Colorado drug review board finds J&J`s Stelara unaffordable
11 Jun 2024 //
FIERCE PHARMA
Rani Oral Biosimilar Ustekinumab Data At DDW 2024
09 May 2024 //
GLOBENEWSWIRE
Teva Pharm to launch Humira biosimilar as Q1 profit misses estimates
08 May 2024 //
REUTERS
Sandoz`s Ustekinumab Biosimilar Pyzchiva Approved In EU
22 Apr 2024 //
GLOBENEWSWIRE
Alvotech and Teva gain FDA approval of Selarsdi for psoriasis
17 Apr 2024 //
PHARMACEUTICAL TECHNOLOGY
Alvotech USA`s Biologic Selarsdi (ustekinumab-aekn) Receives Approval In US
16 Apr 2024 //
FDA
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™
16 Apr 2024 //
BUSINESSWIRE
Centocor`s Biologic Stelara (ustekinumab) Receives Approval in the U.S.
18 Mar 2024 //
FDA
Janssen-Cilag`s Biologic Stelara (ustekinumab) Receives Approval in the U.S.
18 Mar 2024 //
FDA
Biocon Biologics gears up to challenge Stelara in the US
29 Feb 2024 //
FIERCE PHARMA
Alvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar
15 Feb 2024 //
GLOBENEWSWIRE
J&J profit edges past Street view after deals delay Stelara competition
24 Jan 2024 //
REUTERS
STADA and Alvotech Secure Approval for Uzpruvo
10 Jan 2024 //
GLOBENEWSWIRE
FDA Accepts for Review BLA for DMB-3115 of Dong-A ST
05 Jan 2024 //
BUSINESSWIRE
J&J, Samsung Bioepis ink Stelara biosimilar settlement
30 Nov 2023 //
FIERCE PHARMA
Alvotech and JAMP Pharma Announce Receipt of Marketing Authorization for Jamteki
14 Nov 2023 //
GLOBENEWSWIRE
STADA and Alvotech receive positive CHMP opinion for ustekinumab biosimilar
10 Nov 2023 //
GLOBENEWSWIRE
HHS says Stelara may be deselected from Medicare negotiations
06 Nov 2023 //
ENDPTS
FDA Approves Interchangeable Biosimilar for Multiple Inflammatory Diseases
01 Nov 2023 //
FDA
AbbVie details Skyrizi data showing superiority over Stelara in Crohn`s
16 Oct 2023 //
PRESS RELEASE
Alvotech Provides Update on Status of U.S. BLA for AVT04
13 Oct 2023 //
PRESS RELEASE
Alvotech Announces Approval in Japan of AVT04, a Biosimilar to Stelara®
25 Sep 2023 //
GLOBENEWSWIRE
AbbVie`s Skyrizi deals blow to J&J`s Stelara in IBD trial
13 Sep 2023 //
FIERCE PHARMA
Sandoz inks deal to commercialize biosim to J&J`s Stelara
12 Sep 2023 //
FIERCE PHARMA
J&J`s Stelara settlement streak rolls on with Fresenius Kabi, Formycon deal
08 Aug 2023 //
FIERCE PHARMA
EMA Accepts MAA for DMB-3115 of Dong-A ST, a Stelara Biosimilar
17 Jul 2023 //
BUSINESSWIRE
J&J inks Stelara biosim settlement with Alvotech and Teva
13 Jun 2023 //
FIERCE PHARMA
Amgen, J&J ink Stelara patent settlement
24 May 2023 //
FIERCE PHARMA
Samsung Bioepis Presents Phase 1 Study Results of SB17 (Ustekinumab)
17 Mar 2023 //
GLOBENEWSWIRE
STELARA Data Support its Established Safety in Inflammatory Bowel Disease
04 Mar 2023 //
PR NEWSWIRE
EMA Confirms Acceptance of Application for AVT04, Proposed Biosimilar to Stelara
10 Feb 2023 //
STADA
J&J sues Amgen over plan to sell drug similar to blockbuster Stelara
01 Dec 2022 //
REUTERS
Janssen challenges Amgen`s Stelara biosimilar ahead of planned 2023 launch
30 Nov 2022 //
ENDPTS
STELARA Demonstrated Sustained Symptomatic & Corticosteroid-Free Remission
10 Oct 2022 //
PRNEWSWIRE
FDA green light for Stelara in children with active PsA
02 Aug 2022 //
THEPHARMALETTER
Amgen Announces Positive Top-Line Results From Phase 3 Study Of ABP 654
18 Apr 2022 //
PRNEWSWIRE
Stelara® shows promise to treat gut diseases in new analyses
28 Oct 2021 //
EUROPEANPHARMACEUTICALREVIEW